

1 **The value of ¹⁸F-FDG-PET/CT in diagnosis and during follow-up in 273 patients with chronic Q fever**

2
3 Ilse J.E. Kouijzer^{1,2,3}, Linda M. Kampschreur⁴, Peter C. Wever⁵, Corneline Hoekstra⁶, Marjo E.E. van Kasteren⁷,
4 Monique G.L. de Jager-Leclercq⁸, Marringje H. Nabuurs-Franssen⁹, Marjolijn C.A. Wegdam-Blans¹⁰, Heidi S.M.
5 Ammerlaan¹¹, Jacqueline Buijs¹², Lioe-Fee de Geus-Oei^{3,13}, Wim J.G. Oyen¹⁴, Chantal P. Bleeker-Rovers^{1,2}

6
7 ¹Department of Internal Medicine, Division of Infectious Diseases, Radboud university medical center,
8 Nijmegen, the Netherlands

9 ²Radboud Expert Centre for Q fever, Radboud university medical center, Nijmegen, the Netherlands

10 ³MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, the
11 Netherlands

12 ⁴Department of Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands

13 ⁵Department of Medical Microbiology and Infection Control, Jeroen Bosch Hospital, 's-Hertogenbosch, the
14 Netherlands

15 ⁶Department of Nuclear Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands

16 ⁷Department of Internal Medicine, Elisabeth Tweesteden Hospital, Tilburg, the Netherlands

17 ⁸Department of Internal Medicine, Bernhoven Hospital, Uden, the Netherlands

18 ⁹Department of Medical Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital, Nijmegen, the
19 Netherlands

20 ¹⁰Department of Medical Microbiology, Laboratory for Pathology and Medical Microbiology (PAMM),
21 Veldhoven, the Netherlands

22 ¹¹Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands

23 ¹²Department of Internal Medicine, Zuyderland Medical Center, Heerlen, the Netherlands

24 ¹³Department of Nuclear Medicine, Leiden University Medical Center, Leiden, the Netherlands

25 ¹⁴The Institute of Cancer Research / The Royal Marsden Hospital, London, U.K. and Department of Nuclear
26 Medicine, Radboud university medical center, Nijmegen, the Netherlands

31 **First and corresponding author**

32 Ilse J.E. Kouijzer (Resident Internal Medicine and Infectious Diseases)

33 Department of Internal Medicine and Infectious Diseases, Radboud university medical center,

34 P.O. Box 9101, 6500 HB, Nijmegen, the Netherlands

35 E-mail: ilsekouijzer@gmail.com, telephone: 0031-24-3618819

36

37 **Word count**

38 4994 words

39

40 **Financial Disclosures**

41 This work was supported by a grant of Q-support (UMCN140926-00)

42

43 **Running title**

44 ¹⁸F-FDG-PET/CT in chronic Q fever

45 **ABSTRACT**

46

47 In 1-5% of all acute Q fever infections, chronic Q fever develops, mostly manifesting as endocarditis, infected
48 aneurysms, or infected vascular prostheses. In this study, we investigated the diagnostic value of ¹⁸F-
49 fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG-PET/CT) in chronic Q fever
50 at diagnosis and during follow-up.

51 **Methods:** All Dutch adult patients suspected of chronic Q fever who were diagnosed since 2007 were
52 retrospectively included until March 2015 when at least one ¹⁸F-FDG-PET/CT was performed. Clinical data and
53 results from ¹⁸F-FDG-PET/CT at diagnosis and during follow-up were collected. ¹⁸F-FDG-PET/CT scans were
54 prospectively reevaluated by three nuclear medicine physicians using a structured scoring system.

55 **Results:** In total, 273 patients with possible, probable, and proven chronic Q fever were included. Of all ¹⁸F-
56 FDG-PET/CT scans performed at diagnosis, 13.5% led to a change in diagnosis. Q fever-related mortality rate in
57 patients with and without vascular infection based on ¹⁸F-FDG-PET/CT was 23.8% and 2.1%, respectively ($p=$
58 0.001). When adding ¹⁸F-FDG-PET/CT as a major criterion to the modified Duke criteria, 17 patients (1.9-fold
59 increase) had definite endocarditis. At diagnosis, 19.6% of ¹⁸F-FDG-PET/CT led to treatment modification.
60 During follow-up, 57.3% of ¹⁸F-FDG-PET/CT resulted in treatment modification.

61 **Conclusions:** ¹⁸F-FDG-PET/CT is a valuable diagnostic technique in diagnosis of chronic Q fever and during
62 follow-up often leading to a change in diagnosis and/or treatment modification, also providing important
63 prognostic information on patient survival.

64

65

66 **Key-words**

67 Q-fever; ¹⁸F-FDG-PET/CT; vascular infection; endocarditis

68 **INTRODUCTION**

69

70 Q fever is a zoonosis with a worldwide distribution caused by the intracellular bacterium *Coxiella burnetii*. In
71 the Netherlands, a large Q fever outbreak occurred between 2007 and 2010 with over 4,000 notified cases of
72 acute Q fever and more than 40,000 infected patients (1). In 1-5% of infections with *C. burnetii*, chronic Q fever
73 infection develops (2,3). In most patients, manifestations of chronic Q fever are endocarditis, infected
74 aneurysms, or infected vascular prostheses. Even if adequate treatment is started, chronic Q fever causes high
75 morbidity and mortality. Many patients with chronic Q fever present when severe complications develop, such as
76 a ruptured aneurysm, with an associated high mortality (4). Therefore, it is important to diagnose chronic Q fever
77 in an early stage and start adequate treatment as soon as possible. However, diagnosing chronic Q fever is often
78 difficult.

79 ¹⁸F-FDG-PET/CT is very effective in localizing metastatic infection in case of bacteremia (5,6). In
80 endocarditis, diagnosis is made using the modified Duke criteria with evidence of endocardial involvement on
81 echocardiography as one of the major criteria (7). The value of ¹⁸F-FDG-PET/CT for diagnosing native valve
82 endocarditis has been investigated, but sensitivity is not optimal (8,9). For prosthetic valve endocarditis, ¹⁸F-
83 FDG-PET/CT has shown promising results and recently ¹⁸F-FDG-PET/CT was added to the European Society of
84 Cardiology criteria as a major criterion for diagnosing prosthetic valve endocarditis (10). In diagnosing vascular
85 infection, ¹⁸F-FDG-PET/CT has proven its effectiveness (11,12), also in chronic Q fever vascular infection
86 (13,14).

87 In this study, we investigated the diagnostic value of ¹⁸F-FDG-PET/CT in patients with chronic Q fever at
88 the time of diagnosis and during follow-up, and also the effect on treatment modification. We also studied
89 whether addition of ¹⁸F-FDG-PET/CT to the modified Duke criteria can improve diagnosis of chronic Q fever
90 endocarditis.

91 MATERIALS AND METHODS

92

93 Patients and study design

94 All Dutch patients ≥ 18 years with possible, probable, or proven chronic Q fever according to the Dutch
95 consensus guideline (Table 1) (15) were included when one or more ^{18}F -FDG-PET/CT-scans were performed.

96 All Dutch hospitals treating chronic Q fever patients were actively approached to include all chronic Q fever
97 patients who were detected since the start of the Dutch Q fever epidemic in 2007. Patients were included in this
98 study until March 2015. Data on patient characteristics, signs and symptoms, microbiological results, ^{18}F -FDG-
99 PET/CT results and their consequences, echocardiography, type and duration of antibiotic therapy, and outcome
100 were collected from patient records. The institutional review board approved this retrospective study and the
101 requirement to obtain informed consent was waived.

102

103 Diagnostic work-up

104 Patients included in this study underwent ^{18}F -FDG-PET/CT in the hospital where they were evaluated
105 and/or treated for their chronic Q fever. For this study, Siemens Biograph (16, 20, mCT40) and Philips Gemini
106 (GXL16, TF16, TF64) PET/CT-scanners were used. Before ^{18}F -FDG injection, all patients fasted and any
107 glucose- or insulin-containing infusions were discontinued for at least 6 hours. In 22.5% of patients, a low
108 carbohydrate fat allowed diet was followed 24 hours before ^{18}F -FDG-PET/CT. One hour after injection of ^{18}F -
109 FDG, a low dose CT scan of the area between proximal femora and skull base was acquired for anatomical
110 correlation and attenuation correction of the PET data. To avoid interpretation bias, the retrospectively acquired
111 ^{18}F -FDG-PET/CT images were prospectively reevaluated by 3 nuclear medicine physicians (CH, LFdG, WJGO)
112 without knowledge of prior clinical evaluation and blinded for any clinical information or patient history. For
113 evaluation, specific criteria for assessment of vascular infection and endocarditis were used (Table 2). ^{18}F -FDG-
114 PET/CT assessed by this structured scoring system was compared to the final clinical diagnoses, which were
115 based on medical history, physical examination, laboratory and microbiological results, and imaging.

116 Microbiological analysis for the diagnosis of chronic Q fever consisted of serology and polymerase
117 chain reaction (PCR) for *C. burnetii* DNA on plasma, serum, and tissue. An indirect fluorescent-antibody assay
118 (IFA; Focus Diagnostics, Inc., Cypress, CA, USA) was used for serologic analysis in all patients. The modified
119 Duke criteria were used for diagnosing infective endocarditis (7). Whether sensitivity of these criteria could be
120 improved by adding the result of the ^{18}F -FDG-PET/CT was studied in an attempt to improve the diagnostic

121 criteria for chronic Q fever endocarditis. The impact of ^{18}F -FDG-PET/CT on treatment modification was
122 determined by **two study co-authors** (IJEK and CBR) for all cases based on all available clinical information as
123 registered in the patient records and classified as follows: 1) initiation of antibiotic treatment, 2) discontinuation
124 of antibiotic treatment, 3) changing type of antibiotic treatment, 4) continuation of antibiotic treatment, and 5)
125 surgical intervention. If the result of ^{18}F -FDG-PET/CT did not result in any modification, this was also
126 reported.

127

128 **Statistical methods**

129 All data were analyzed using SPSS version 20 (SPSS, Inc., Chicago, IL). Two-tailed chi-square test or
130 Wilcoxon tests were used to compare qualitative data. Mean values were analyzed by Student's t-tests.

131 **RESULTS**

132

133 In total, 379 patients had a diagnosis of proven, probable, or possible chronic Q fever according to the
134 Dutch consensus guideline (15). In 273 patients, ¹⁸F-FDG-PET/CT was performed and in 230 of these patients,
135 ¹⁸F-FDG-PET/CT scans were performed at diagnosis of chronic Q fever. During follow-up, 218 ¹⁸F-FDG-
136 PET/CT scans were performed in 143 patients. Reasons for follow-up ¹⁸F-FDG-PET/CT were **suspected new**
137 **complications** (175, 80.3%) or end of treatment evaluation (43, 19.7%). **Suspected new complications** in chronic
138 Q fever patients, **such as new abscesses or spondylodiscitis or progression of the primary infection during**
139 **treatment**, were suspected in case of new positive serum PCR, no change in antibody titer after one year of
140 treatment, or increasing titers, and/or new or increasing complaints. In 43 patients, only follow-up ¹⁸F-FDG-
141 PET/CT scans were performed without a baseline ¹⁸F-FDG-PET/CT at diagnosis. In these patients, diagnosis of
142 chronic Q fever was based on a combination of serology, PCR, and/or CT imaging. Of all 273 patients, 147
143 patients were eventually diagnosed with proven chronic Q fever, 60 patients with probable chronic Q fever, and
144 66 patients with possible chronic Q fever. Of all patients, 199 (72.9%) were male and the mean age at diagnosis
145 was 65.0 years. A known history of acute Q fever was identified in 105 patients (38.5%). Risk factors and
146 outcome for all patients are shown in Table 3. **Overall, in 93 patients (63.3%) with proven chronic Q fever,**
147 **infectious foci were seen on ¹⁸F-FDG-PET/CT. Of all 448 ¹⁸F-FDG-PET/CT scans performed in this study, 438**
148 **scans could be reevaluated as 10 scans were not available for reevaluation.**

149

150 **Vascular infection**

151 Of all 142 ¹⁸F-FDG-PET/CT scans performed at diagnosis of chronic Q fever with grade 1 and grade 2
152 vascular patterns (Table 2), 3 patients (2.1%) **had a clinical diagnosis of** vascular infection. Of these patients,
153 reevaluated follow-up ¹⁸F-FDG-PET/CT confirmed this diagnosis of **vascular infection** in 2 patients and in one
154 patient follow-up ¹⁸F-FDG-PET/CT was missing but diagnosis was confirmed by positive PCR on tissue of the
155 aneurysm. **Results of all reevaluated ¹⁸F-FDG-PET/CT scans performed at diagnosis of chronic Q fever for**
156 **vascular infection (Fig. 1.) and Q-fever related mortality are shown in Table 4.** Of 29 scans with homogeneous
157 FDG uptake pattern, 16 scans (55.2%) were considered as inflammation without infection and 13 scans (44.8%)
158 as vascular infection due to peri-graft soft tissue involvement of which 9 cases had positive PCR on vascular
159 tissue. Q fever-related mortality rates in patients with and without vascular infection based on this scoring
160 system were 23.8% and 2.1%, respectively ($p= 0.001$).

161

162 **Endocarditis**

163 Of all chronic Q fever patients, 9 patients (3.3%) had definite endocarditis according to the modified
164 Duke criteria and 59 patients (21.6%) had possible endocarditis. In 36 of all patients, no echocardiography was
165 performed. By reevaluating ¹⁸F-FDG-PET/CT, the heart showed diffuse ¹⁸F-FDG-uptake (grade 2) on 300 ¹⁸F-
166 FDG-PET/CT-scans in 193 patients making a reliable assessment of the heart impossible. In 92.3% of these
167 scans, no prior low carbohydrate fat allowed diet was followed. Of all 80 patients in whom ¹⁸F-FDG-PET/CT
168 were assessable for the heart region, 10 ¹⁸F-FDG-PET/CT scans (12.5%) showed focal ¹⁸F-FDG-uptake
169 indicating endocarditis (grade 3) (Fig. 2). Of these 10 patients, 2 (20.0%) had a diagnosis of definite endocarditis
170 according to the modified Duke criteria. Of all 70 patients without relevant ¹⁸F-FDG-uptake of the heart valve
171 (grade 1), 2 patients (2.9%) had definite endocarditis according to the modified Duke criteria. Of all 237 patients
172 who underwent echocardiography, 9 had valve vegetations on echocardiography. Of these 9 patients, evaluation
173 of ¹⁸F-FDG-PET/CT showed grade 1 ¹⁸F-FDG-uptake in 2 patients, grade 2 in 4 patients, and grade 3 in 3
174 patients.

175 When adding ¹⁸F-FDG-PET/CT as a major criterion to the Duke criteria, 17 patients (7.2%) had a
176 definite endocarditis. In Table 5, the modified Duke criteria were compared with the Duke criteria including ¹⁸F-
177 FDG-PET/CT as a major criterion by a two-tailed Wilcoxon test, which showed a significant difference in the
178 number of patients with proven endocarditis ($p = 0.008$). Of the 8 patients who had the diagnosis definite
179 endocarditis based on the ¹⁸F-FDG-PET/CT result, 5 patients had a positive PCR on blood, 2 had a valve
180 prosthesis, and 6 had no other infectious foci. Of these 8 patients, 2 patients were originally diagnosed with
181 possible endocarditis and 6 patients with rejected endocarditis according to the modified Duke criteria.

182

183 **¹⁸F-FDG-PET/CT and treatment modification**

184 At diagnosis, after a negative PCR result on blood and/or tissue was obtained, ¹⁸F-FDG-PET/CT
185 contributed to a change in diagnosis in 31 patients (13.5%). In all these patients, the diagnosis probable chronic
186 Q fever changed to proven chronic Q fever. At diagnosis, ¹⁸F-FDG-PET/CT contributed to treatment
187 modification in 45 patients (19.6%). In 37 patients (16.1%), ¹⁸F-FDG-PET/CT led to a start of antibiotic
188 treatment and in 2 patients (0.9%) antibiotic treatment was changed. In 6 patients (2.6%) the ¹⁸F-FDG-PET/CT
189 result led to surgical intervention.

190 At follow-up, ¹⁸F-FDG-PET/CT performed to make a decision on stopping antibiotic treatment was

191 negative in 31 cases (72.1%) and showed suspicion of ongoing infectious foci in 12 cases (27.9%). Of the 175
192 follow-up ¹⁸F-FDG-PET/CT scans performed because of suspected **new complications**, 84 scans (48.0%) were
193 negative. Of all follow-up ¹⁸F-FDG-PET/CT scans, 125 scans (57.3%) led to treatment modification, 21 scans
194 (9.6%) led to discontinuation of antibiotic treatment, 7 scans (3.2%) led to a change in antibiotic treatment, and
195 in 97 scans (44.5%) the result of ¹⁸F-FDG-PET/CT contributed to the decision to continue antibiotic treatment
196 (Fig. 3). In 6 patients (3.4%), ¹⁸F-FDG-PET/CT led also to surgical intervention.
197

198 **DISCUSSION**

199

200 In this study, we investigated the value of ¹⁸F-FDG-PET/CT in diagnosis and during follow-up in
201 patients with chronic Q fever. Specific guidelines when to perform ¹⁸F-FDG-PET/CT are lacking. Because of the
202 largest Q fever outbreak ever reported in the Netherlands between 2007 and 2010, it was possible to analyze the
203 value of ¹⁸F-FDG-PET/CT in a large cohort of 273 patients with chronic Q fever.

204 The results of our study show that ¹⁸F-FDG-PET/CT is a valuable diagnostic technique, with a
205 contribution to the diagnosis of chronic Q fever in 13.5% of patients after serology and PCR has already been
206 performed. In follow-up of chronic Q fever, ¹⁸F-FDG-PET/CT performed for decision making in stopping
207 antibiotic treatment showed persisting focal infection in 27.9%, although patients had low serological titers and
208 were asymptomatic. This emphasizes the important value of ¹⁸F-FDG-PET/CT in follow-up of chronic Q fever.
209 ¹⁸F-FDG-PET/CT is also valuable for decision making in treatment of chronic Q fever patients with 19.6% of
210 treatment modification at diagnosis and in 57.3% during follow-up of chronic Q fever. Moreover, ¹⁸F-FDG-
211 PET/CT provided important prognostic information on patient survival.

212 Several case reports indicated that ¹⁸F-FDG-PET/CT could be valuable in diagnosing chronic Q fever
213 (16-18). One study on a screening program in patients with chronic Q fever reported that ¹⁸F-FDG-PET/CT
214 showed vascular infection in 5 out of 10 patients (19). In a retrospective study in 52 patients with chronic Q
215 fever, ¹⁸F-FDG-PET/CT was performed in 13 out of 18 patients with proven chronic Q fever and was helpful in
216 77% showing 7 infected vascular prostheses and 3 infected aneurysms (13). Recently, a Dutch study reported
217 that ¹⁸F-FDG-PET/CT showed a vascular infection in 6 out of 13 patients with proven chronic Q fever based on
218 positive PCR for *C. burnetii* and known aneurysm or vascular prosthesis (14).

219 Very recently, Eldin et al. (20) reported on a case series of 99 patients with abnormalities seen on ¹⁸F-
220 FDG-PET/CT performed after diagnosis of both acute and chronic Q fever. ¹⁸F-FDG-PET/CT contributed to a
221 change in diagnosis in 62.6% of patients. Limitations of the study of Eldin et al. are the fact that only ¹⁸F-FDG-
222 PET/CT-scans showing signs of infection were included and that no central reevaluation of ¹⁸F-FDG-PET/CT
223 scans was performed. Also, because both acute and chronic Q fever patients were included in the study of Eldin
224 et al., a comparison with our study is difficult. Furthermore, the 62.6% of change in diagnosis was only based on
225 a new abnormality seen on ¹⁸F-FDG-PET/CT, but it is not clear whether these abnormalities were Q fever foci
226 because the exact clinical context of the patients was not mentioned.

227 In vascular chronic Q fever infection, a structured protocol for assessment of ¹⁸F-FDG-PET/CT is

228 lacking. Also, non-infected vascular prostheses may show increased ^{18}F -FDG uptake due to postsurgical
229 inflammation (21,22). In our study, we used a structured grading score for **prospectively** reevaluation of the ^{18}F -
230 FDG-PET/CT scans, **which is a modified adaptation of** scoring systems used in other studies on vascular
231 infection (12,22). The value of this score as shown in Table 2 was endorsed by the fact that patients with grade 1
232 or 2 had no vascular infection in 97.9% and a significantly lower Q fever-related mortality rate. Our score shows
233 that a homogeneous uptake pattern does not exclude vascular infection, especially in case of involvement of
234 surrounding tissue and also considering the high amount of positive PCR on vascular tissue in this group. It is
235 important that interpretation of ^{18}F -FDG-PET/CT is done multidisciplinary based on the individual clinical
236 context.

237 In prosthetic valve endocarditis (not caused by Q fever), the diagnostic value of ^{18}F -FDG-PET/CT has
238 been investigated and has shown promising results (23). Recently, ^{18}F -FDG-PET/CT was added to the European
239 Society of Cardiology modified diagnostic criteria as a major criterion for prosthetic valve endocarditis (10).
240 Sensitivity of ^{18}F -FDG-PET/CT in diagnosing native valve endocarditis is not optimal (8,9). In chronic Q fever
241 endocarditis, vegetations are small and often not seen on echocardiography (24). As endocardial involvement
242 seen on echocardiography is a major criterion of the modified Duke criteria, many patients with chronic Q fever
243 endocarditis are missed using these criteria. Therefore, a high anti-phase I IgG titer was added earlier to the
244 modified Duke criteria as a major criterion (24). Our study shows that adding increased ^{18}F -FDG valve uptake as
245 a major criterion to the modified Duke criteria, led to a 1.9 fold increase in diagnoses of proven endocarditis.
246 Thus, adding ^{18}F -FDG-PET/CT to the modified Duke criteria for diagnosing chronic Q fever endocarditis could
247 be a valuable improvement since missed diagnoses have always been expected in this disease.

248 Potential limitations of our study are the fact that only chronic Q fever patients who underwent ^{18}F -
249 FDG-PET/CT were included. This could lead to selection bias, as patients with i.e. early death were not included
250 in this study. Also, the lack of additional clinical context in reevaluation of ^{18}F -FDG-PET/CT could have led to
251 less sensitive reading.

252 **CONCLUSION**

253

254 ¹⁸F-FDG-PET/CT is a valuable imaging technique in chronic Q fever and should be performed at
255 diagnosis and should be considered during follow-up when new complications are suspected or before end of
256 treatment when the first ¹⁸F-FDG-PET/CT scan was abnormal. Scans should be interpreted using a structured
257 protocol. Addition of the ¹⁸F-FDG-PET/CT to the modified Duke criteria in patients with chronic Q fever could
258 be valuable.

259 **FINANCIAL DISCLOSURE**

260

261 This work was supported by a grant of Q-support (UMCN140926-00), a Dutch foundation for support
262 of Q fever research and patients.

263

264

265 **ACKNOWLEDGMENTS**

266

267 The authors would like to thank the following physicians treating chronic Q fever patients and institutes
268 for their cooperation in this study: S. Shamelian, internal medicine specialist at Jeroen Bosch Hospital in 's-
269 Hertogenbosch, the Netherlands; N.H.M. Renders, medical microbiologist at Jeroen Bosch Hospital in 's-
270 Hertogenbosch, the Netherlands; Y.E.P. Soethoudt, infectious diseases specialist at Elkerliek Hospital in
271 Helmond, the Netherlands; S.N. Blank, infectious diseases specialist at Maxima Medical Center in Veldhoven,
272 the Netherlands; D. Posthouwer, infectious diseases specialist at Maastricht University Medical Center in
273 Maastricht, the Netherlands; C. Delsing, infectious diseases specialist at Medisch Spectrum Twente Hospital in
274 Enschede, the Netherlands; J.J. Oosterheert, infectious diseases specialist at University Medical Center Utrecht
275 in Utrecht, the Netherlands; S.U.C. Sankatsing, infectious diseases specialist at Diakonessenhuis Hospital in
276 Utrecht, the Netherlands.

277 **REFERENCES**

- 278 1 Hogema BM, Slot E, Molier M, et al. *Coxiella burnetii* infection among blood donors
279 during the 2009 Q-fever outbreak in The Netherlands. *Transfusion*. 2012;52:144-50.
- 280 2 Delsing CE, Kullberg BJ, Bleeker-Rovers CP. Q fever in the Netherlands from 2007-2010.
281 *Neth J Med*. 2010;68:382-387.
- 282 3 Maurin M, Raoult D. Q fever. *Clin Microbiol Rev*. 1999;12:518-553.
- 283 4 Kampschreur LM, Delsing CE, Groenwold RH, et al. Chronic Q fever in The Netherlands
284 5 years after the start of Q fever epidemic: results from the Dutch chronic Q fever
285 database. *J Clin Microbiol*. 2014;52:1637-1643.
- 286 5 Vos FJ, Bleeker-Rovers CP, Sturm PD, et al. 18F-FDG PET/CT for detection of metastatic
287 infection in Gram-positive bacteremia. *J Nucl Med*. 2010;51:1234-1240.
- 288 6 Vos FJ, Bleeker-Rovers CP, Kullberg BJ, Adang EM, Oyen WJ. Cost-effectiveness of
289 routine 18F-FDG- PET/CT in high-risk patient with Gram-positive bacteremia. *J Nucl*
290 *Med*. 2011;52:1673-1678.
- 291 7 Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the
292 diagnosis of infective endocarditis. *Clin Infect Dis*. 2000;30:633-638.
- 293 8 Kouijzer IJE, Vos FJ, Jansen MJR, van Dijk APJ, Oyen WJG, Bleeker-Rovers CP. The
294 value of 18F- FDG-PET/CT in diagnosing endocarditis. *Eur J of Nucl Med and Mol*
295 *Imaging*. 2013;40:1102-1107.
- 296 9 Salomaki SP, Saraste A, Kemppainen J, et al. 18F-FDG positron emission
297 tomography/computed tomography in infective endocarditis. *J Nucl Cardiol*. 2017;24:195-
298 206.
- 299 10 Habib G, Lancelotti P, Antunes MJ, et al. 2015 ESC Guidelines for the management of
300 infective endocarditis: the task force for the management of infective endocarditis of the

301 European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-
302 Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur*
303 *Heart J.* 2015;36:3075-3128.

304 11 Keidar Z, Engel A, Hoffman A, Israel O, Nitecki S. Prosthetic vascular graft infection: the
305 role of 18F- FDG-PET/CT. *J Nucl Med.* 2007;48:1230-1236.

306 12 Bruggink JL, Glaudemans AW, Saleem BR, et al. Accuracy of FDG- PET/CT in the
307 diagnostic work-up of vascular prosthetic graft infection. *Eur J Vasc Endovasc Surg.*
308 2010;40:348-354.

309 13 Barten DG, Delsing CE, Keijmel SP, et al. Localizing chronic Q fever: a challenging
310 query. *BMC Infect Dis.* 2013;13:413.

311 14 Hagenaaers JCJP, Wever PC, Vlake AW, et al. Value of FDG-PET/CT in diagnosing
312 chronic Q fever in patients with central vascular disease. *Neth J Med.* 2016;74:301-308.

313 15 Wegdam-Blans MC, Kampschreur LM, Delsing CE, et al. Dutch Q fever Consensus
314 Group. Chronic Q fever: review of the literature and a proposal of new diagnostic criteria.
315 *J Infect.* 2012;64:247-259.

316 16 Alwis L, Balan K, Wright P, Lever A, Carmichael A. Bone marrow involvement in Q
317 fever - detection by fluorine-18-labelled fluorodeoxyglucose PET. *Lancet Infect Dis.*
318 2009;9:718.


319 17 Merhej V, Cammilleri S, Piquet P, Casalta JP, Raoult D. Relevance of the positron
320 emission tomography in the diagnosis of vascular graft infection with *Coxiella burnetii*.
321 *Comp Immunol Microbiol Infect Dis.* 2012;35:45-49.

322 18 Angelakis E, Edouard S, Lafranchi MA, Pham T, Lafforgue P, Raoult D. Emergence of Q
323 fever arthritis in France. *J Clin Microbiol.* 2014;52:1064-1067.

- 324 19 Wegdam-Blans MC, Stokmans RA, Tjhie JH, et al. Targeted screening as a tool for the
325 early detection of chronic Q fever patients after a large outbreak. *Eur J Clin Microbiol*
326 *Infect Dis.* 2013;32:353-359.
- 327 20 Eldin C, Melenotte C, Million M, et al. 18F-FDG-PET/CT as a central tool in the shift
328 from chronic Q fever to *Coxiella burnetii* persistent focalized infection: a consecutive case
329 series. *Medicine.* 2016;95:34(e4287).
- 330 21 Keidar Z, Pirmisashvili N, Leiderman M, Nitecki S, Israel O. 18F-FDG uptake in
331 noninfected prosthetic vascular grafts: incidence, patterns, and changes over time. *J Nucl*
332 *Med.* 2014;55:392-395.
- 333 22 Sah BR, Husmann L, Mayer D, et al. Diagnostic performance of 18F-FDG-PET/CT in
334 vascular graft infections. *Eur J Vasc Endovasc Surg.* 2015;49:455-464.
- 335 23 Pizzi, MN, Roque A, Fernandez-Hidalgo N, et al. Improving the diagnosis of infective
336 endocarditis in prosthetic valves and intracardiac devices with 18F-fluorodeoxyglucose
337 positron emission tomography/computed tomography angiography: initial results at an
338 infective endocarditis referral center. *Circulation.* 2015;132:1113-1126.
- 339 24 Fournier PE, Casalta JP, Habib G, Messana T, Raoult D. Modification of the diagnostic
340 criteria proposed by the Duke endocarditis service to permit improved diagnosis of Q fever
341 endocarditis. *Am J Med.* 1996;100:629-633.

342 **FIGURE LEGENDS**

343



344

345 **FIGURE 1.**


346 ¹⁸F-FDG-PET/CT-scan of a 72-year-old man with proven chronic Q fever with an infected endovascular aortic
347 graft and psoas abscess. This patient had vascular surgery six months after initiation of antibiotic therapy with
348 doxycyclin and hydroxychloroquin because of the severity of infection. Four years later, this patients is still on
349 antibiotic treatment because of persisting chronic Q fever infection.

350

351

352

353



354


355 **FIGURE 2.**

356 ¹⁸F-FDG-PET/CT-scan of a 67-year-old man with a history of acute Q fever and analysis because of severe
357 fatigue. Serology for *C. burnetii* showed increased antiphase 1 IgG, PCR on blood was negative.

358 Transesophageal echocardiography was negative for endocarditis, but ¹⁸F-FDG-PET/CT showed highly

359 increased ¹⁸F-FDG uptake of his native mitral valve. This patient was treated for almost 2 years with antibiotic

360 therapy because of chronic Q fever endocarditis.



362

363 **FIGURE 3.**

364 ^{18}F -FDG-PET/CT-scan of a 64-year-old man with proven chronic Q fever with an infected aneurysm and
 365 infected vascular graft in the aorta. The upper ^{18}F -FDG-PET/CT-scan shows the vascular infection before
 366 initiation of antibiotic treatment with doxycyclin and hydroxychloroquin. The middle ^{18}F -FDG-PET/CT-scan
 367 shows the same area after one year of treatment. The lower ^{18}F -FDG-PET/CT-scan was performed two years
 368 after start of treatment and did no longer show vascular infection and therefore antibiotic treatment was
 369 discontinued. Four years later this patients died due to a septic cholangitis. Autopsy did not show any Q fever
 370 foci and PCR for *C. burnetii* on several tissues including the aorta was negative.

371 **TABLES**

372

373 **TABLE 1. Dutch consensus guidelines on chronic Q fever diagnosis (15)**

Diagnosis	Characteristics
Proven chronic Q fever	Positive <i>Coxiella burnetii</i> PCR in blood or tissue OR IFA of ≥ 1024 for <i>C. burnetii</i> phase I IgG with either definite endocarditis according to the modified Duke criteria or proven large vessel or prosthetic infection by imaging techniques (^{18}F -FDG-PET/CT, MRI, CT, US).
Probable chronic Q fever	IFA of ≥ 1024 for <i>C. burnetii</i> phase I IgG AND valvulopathy not meeting the modified Duke criteria OR known aneurysm and/or vascular or cardiac valve prosthesis without signs of infection by imaging techniques (TTE/TEE, ^{18}F -FDG-PET/CT, MRI, CT, US) OR suspected osteomyelitis, hepatitis, or pericarditis as manifestations of chronic Q fever OR pregnancy OR symptoms and signs of chronic infection such as fever, weight loss, night sweats, hepatosplenomegaly, and persistent ESR or CRP OR granulomatous tissue inflammation as proven by histological examination OR immunocompromised state.
Possible chronic Q fever	IFA of ≥ 1024 for <i>C. burnetii</i> phase I IgG without manifestations meeting the criteria for proven or probable chronic Q fever.

374

375 PCR= polymerase chain reaction. IFA= immunofluorescence assay. IgG= immunoglobulin G. ^{18}F -FDG= ^{18}F -
 376 fluorodeoxyglucose. PET/CT= positron emission tomography/computed tomography. MRI: magnetic resonance
 377 imaging. CT= computed tomography. US= ultrasound. TTE= transthoracic echocardiography. TEE=
 378 transesophageal echocardiography. ESR= erythrocyte sedimentation rate. CRP= C-reactive protein.

379

380

381

382

383

384

385

386

387

388

389

390 **TABLE 2. Interpretation of ¹⁸F-FDG-PET/CT combining a visual grading score and uptake pattern**

391

Vascular infection	
Grade 1	¹⁸ F-FDG-uptake similar to background
Grade 2*	Low ¹⁸ F-FDG-uptake comparable to uptake by inactive muscles and fat, and above background but below liver
Grade 3*	Moderate ¹⁸ F-FDG-uptake clearly visible and higher than the uptake by inactive muscles and fat, and similar to liver uptake
Grade 4*	Strong ¹⁸ F-FDG-uptake clearly above liver uptake
Interpretation	
No vascular infection	Grade 1 and 2
Inflammation	Grade 3 and 4 and homogeneous uptake pattern without peri-graft soft tissue involvement
Vascular infection	Grade 3 and 4 and inhomogeneous uptake pattern with or without peri-graft soft tissue involvement
Endocarditis	
Grade 1	No relevant ¹⁸ F-FDG-uptake of the heart
Grade 2†	Diffuse ¹⁸ F-FDG-uptake in the heart (reflecting normal uptake in myocardium)
Grade 3	Focal ¹⁸ F-FDG-uptake in the heart with or without diffuse low-level uptake in the myocardium
Interpretation	
No endocarditis	Grade 1
Evaluation not possible	Grade 2
Endocarditis	Grade 3

392

393 * An additional ‘a’ for homogeneous ¹⁸F-FDG-uptake and ‘b’ for inhomogeneous ¹⁸F-FDG uptake was

394 registered.

395 † Evaluation of the heart valves for endocarditis was not possible due to diffuse myocardial ¹⁸F-FDG-uptake.

396

397

398

399

400

401

402

403 **TABLE 3. Risk factors and outcome of all patients with proven, probable, and possible chronic Q fever**

404

	Proven chronic Q fever number of patients	Probable chronic Q fever number of patients	Possible chronic Q fever number of patients
Number of patients	147	60	66
Diagnostics			
Positive PCR blood + tissue (%)	25 (17.0)	0	0
Positive PCR blood only (%)	58 (39.5)	0	0
Positive PCR tissue only (%)	27 (18.4)	0	0
Anti-phase I IgG at diagnosis (range)	4096 (256-131071)	4096 (512-65536)	2048 (1024-32768)
Vascular prosthesis (%)			
Infected vascular prosthesis (%)	76 (51.7)	17 (28.3)	0
Known aneurysm (%)			
Infected aneurysm (%)	63 (82.9)	0	0
Cardiac valve prosthesis (%)			
Infected cardiac valve prosthesis (%)	44 (29.9)	8 (13.3)	0
Cardiac valve prosthesis (%)			
Infected cardiac valve prosthesis (%)	34 (77.3)	0	0
Cardiac valve prosthesis (%)			
Infected cardiac valve prosthesis (%)	26 (17.7)	10 (16.7)	0
Modified Duke criteria			
- Definite endocarditis (%)	9 (6.1)	0	0
- Possible endocarditis (%)	37 (25.2)	19 (31.7)	3 (4.5)
- Rejected endocarditis* (%)	77 (52.4)	37 (61.7)	55 (83.3)
Other preexisting valvular disease (%)	13 (8.9)	10 (16.7)	1 (1.5)
Pacemaker (%)	5 (3.4)	1 (1.7)	0
Intra-cardiac defibrillator (%)	2 (1.4)	2 (3.3)	0
Other infection			
Other vascular infection (%)	3 (2.0)	0	0
Other metastatic infection † (%)	24 (16.3)	0	0
Mortality			
Q fever related	18 (12.2)	1 (1.7)	0
Overall mortality	33 (22.4)	8 (13.3)	8 (12.1)

405 * In 36 patients with chronic Q fever no echocardiography was performed.

406 † Other metastatic foci were pulmonary foci (n = 4), cutaneous foci (n = 2), spinal infection (n = 3), psoas
407 abscesses (n = 11), and both a psoas abscess and spondylodiscitis (n = 4).

408 PCR= polymerase chain reaction. IgG= immunoglobulin G. PTA= percutaneous transluminal angiography.

409

410

411

412 **TABLE 4. Results of 221 reevaluated ¹⁸F-FDG-PET/CT scans at diagnosis of chronic Q fever**

Reevaluation of ¹⁸ F-FDG-PET/CT at diagnosis	Q-fever related mortality
n = 221	n = 18 (%)
No infection: grade 1 and 2	3 (2.1)
n = 142	
Inflammation: grade 3a and 4a without peri-graft soft tissue involvement	0
n = 16	
Infection: grade 3b and 4b with or without peri-graft soft tissue involvement	15 (23.8)
n = 63	

413

414 **TABLE 5. Comparison of ¹⁸F-FDG-PET/CT to the modified Duke criteria for diagnosing endocarditis**
 415

	Modified Duke criteria (%)	Duke criteria including ¹⁸ F-FDG-PET/CT as major criterion (%)	Significance*
Definite endocarditis	9 (3.8)	17 (7.2)	0.008
Possible endocarditis	59 (24.9)	57 (24.1)	0.063
Rejected endocarditis	169 (71.3)	163 (68.8)	0.008
Total	237†	237†	

416

417 * Wilcoxin test, 2-tailed.

418 † In 36 patients, no echocardiography was performed.

419

